Thus, we can conclude that this drug can elicit apoptosis in breast cancer MDA-MB-231 cells, attributing it to the upregulation of caspase-3, downregulation of BCL-xL, and alterations in mitochondrial membrane potential. The gene discussed is BCL2L1; the disease is breast carcinoma.